Sudden sensorineural hearing loss is an otologic emergency defined as ≥30 dB hearing loss across at least 3 consecutive frequencies occurring within 72 hours. [1-2] Incidence is 5–20 per 100,000/year (~4,000 new U.S. cases annually), and the etiology is presumed viral, vascular, or autoimmune in the majority of cases where no identifiable cause is found. [1][3] Early recognition and treatment are critical — initiating steroids within 3 days portends the best outcome. [4]
1. History
- Onset and laterality: Exact time of onset, unilateral vs. bilateral, waking up with hearing loss vs. acute onset during activity
- Aural symptoms: Ear fullness/blockage (most common presenting complaint), tinnitus, hyperacusis [5-6]
- Vestibular symptoms: Vertigo, dizziness, imbalance (present in ~30–40% of cases; concomitant vestibular syndrome may predict worse recovery) [7]
- Progression: Static vs. fluctuating vs. progressive; prior episodes of sudden hearing loss
- Triggers: Recent URI, barotrauma, noise exposure, head trauma, diving, straining
- Important negatives: Ear pain, otorrhea, fever, headache, facial weakness, diplopia, dysarthria, limb weakness/numbness — these suggest alternative or secondary diagnoses [2][5]
2. Alarm Features
- Bilateral sudden hearing loss — warrants immediate evaluation for vertebrobasilar ischemia, autoimmune disease (Susac, Cogan syndrome), or ototoxicity [2][8]
- Focal neurologic findings (facial droop, ataxia, nystagmus, diplopia, dysarthria) — consider posterior fossa stroke (AICA territory) [8]
- Recurrent episodes of sudden hearing loss — raises concern for Menière's disease, autoimmune inner ear disease, or perilymphatic fistula [2]
- Severe vertigo with nystagmus — especially down-beating or direction-changing nystagmus, suggests central pathology
- Constitutional symptoms (weight loss, fevers, rash, joint pain) — consider systemic autoimmune or infectious etiology [3]
3. Medications
- Ototoxic medications to identify: Aminoglycosides (gentamicin), loop diuretics, cisplatin, salicylates (high dose), vancomycin, quinine [8]
- Primary treatment: Oral prednisone 60 mg/day (or 1 mg/kg/day) for 10–14 days with taper — current standard of care despite limited placebo-controlled data [3][5]
- Alternative/salvage: Intratympanic dexamethasone (4–24 mg/mL) or methylprednisolone (≥30 mg/mL), typically 3–4 injections over 7–14 days [2]
- Contraindicated/not recommended: Antivirals, thrombolytics, vasodilators, and vasoactive substances should not be routinely prescribed per AAO-HNS guidelines [2]
- Steroid cautions: Screen for diabetes (glucose monitoring), uncontrolled hypertension, active infection, psychiatric history, GI ulcer disease before initiating high-dose steroids [9]
4. Diet
- Low-sodium diet may be recommended if Menière's disease is in the differential (endolymphatic hydrops)
- Adequate hydration — theoretical benefit for vascular etiologies
- Caffeine and alcohol — no strong evidence for restriction, but some clinicians advise moderation during acute phase
- No specific dietary intervention has proven efficacy for idiopathic SSNHL
5. Review of Systems
- ENT: Tinnitus, aural fullness, otorrhea, otalgia, prior ear surgery
- Neurologic: Vertigo, facial weakness/numbness, visual changes, ataxia, headache, diplopia
- Rheumatologic: Joint pain, rash, oral ulcers, dry eyes/mouth, Raynaud phenomenon (autoimmune etiologies) [3]
- Infectious: Recent URI, tick exposure (Lyme), sexual history (syphilis, HIV) [10]
- Vascular: History of stroke/TIA, cardiovascular risk factors
- Psychiatric: Mood changes, sleep disturbance (relevant for steroid side effects)
6. Collateral History and Family History
- Family history of hearing loss, autoimmune disease, neurofibromatosis type 2 (bilateral vestibular schwannomas)
- Occupational noise exposure history
- Social context: Impact on communication, work, driving safety
- Medication list from pharmacy or family members (ototoxic drug exposure)
7. Risk Factors
- Vascular: Hypertension, diabetes, hyperlipidemia, smoking, cardiovascular disease — retrospective cohorts show higher stroke risk after SSNHL, suggesting vascular involvement [3][11]
- Infectious: Recent viral illness (HSV-1, EBV, CMV, mumps, COVID-19) [6][12]
- Autoimmune: Known autoimmune disease (SLE, RA, Behçet, scleroderma, antiphospholipid syndrome) [3]
- Age: Most common in adults 40–60 years [13]
- Hypercoagulable states: Sickle cell disease, Waldenström macroglobulinemia, antiphospholipid antibodies [3]
8. Differential Diagnosis
- Vestibular schwannoma (acoustic neuroma) — must be excluded in all cases with MRI; present in ~1–3% of SSNHL [2][5]
- Posterior fossa stroke (AICA territory) — especially with vertigo, nystagmus, ataxia, or bilateral hearing loss [8]
- Menière's disease — fluctuating low-frequency hearing loss, episodic vertigo, tinnitus, aural fullness [6]
- Autoimmune inner ear disease — bilateral, fluctuating, steroid-responsive; associated with systemic autoimmune conditions [3]
- Perilymphatic fistula — history of barotrauma, straining, or ear surgery
- Multiple sclerosis — demyelinating lesion of CN VIII or brainstem [5]
- Ototoxicity — aminoglycosides, cisplatin, high-dose salicylates [8]
- Conductive hearing loss mimics — cerumen impaction, otitis media/effusion, TM perforation (must be excluded first) [2]
- Leptomeningeal carcinomatosis — variable cranial nerve dysfunction with encephalopathy [14]
- Susac syndrome — triad of encephalopathy, branch retinal artery occlusion, SNHL [3]
9. Past Medical History
- Prior episodes of sudden hearing loss or hearing fluctuation
- Known autoimmune disease, vasculitis, or hypercoagulable state
- History of ear surgery, chronic ear disease, or noise exposure
- Diabetes, hypertension, cardiovascular disease (relevant for vascular etiology and steroid management)
- Prior head/ear trauma
- History of radiation to head/neck [15]
10. Physical Exam
- Otoscopy: Examine for cerumen impaction, TM perforation, middle ear effusion, cholesteatoma — must exclude conductive causes [2]
- Tuning fork tests:
- Weber test: Sound lateralizes away from the affected ear in SNHL (toward the affected ear in conductive loss) [5]
- Rinne test: Air conduction > bone conduction bilaterally in SNHL (abnormal Rinne in conductive loss)
- Cranial nerve exam: Especially CN V, VII, VIII — facial weakness suggests CPA lesion or stroke
- Cerebellar exam: Gait, finger-to-nose, Romberg — ataxia raises concern for posterior fossa pathology [8]
- Nystagmus assessment: Spontaneous, gaze-evoked, or positional — direction-changing or vertical nystagmus suggests central etiology
- Vital signs: Hypertension, fever
11. Lab Studies
- Routine labs are NOT recommended per AAO-HNS guidelines for uncomplicated unilateral SSNHL [2]
- Directed labs when clinical suspicion warrants:
- RPR/VDRL (syphilis)
- Lyme titers (endemic areas)
- HIV testing
- ANA, ESR, CRP (autoimmune disease)
- CBC, BMP (if systemic illness suspected)
- Coagulation studies (hypercoagulable state)
- Glucose/HbA1c (pre-steroid baseline and vascular risk)
- Bilateral SSNHL should prompt broader laboratory evaluation for systemic disease [8][10]
12. Imaging
- MRI with gadolinium of the internal auditory canals (IACs) — gold standard to exclude retrocochlear pathology (vestibular schwannoma, meningioma, demyelination, stroke); recommended for all patients with confirmed SSNHL [2]
- 3D FLAIR sequences pre/post-gadolinium increase sensitivity for cochlear inflammation [2]
- Overall rate of pathogenic MRI abnormalities: 4.4%–13.75% [2]
- CT head is NOT recommended routinely in the initial evaluation [2]
- CT temporal bone may be considered if MRI is contraindicated or if conductive/mixed loss is suspected
- If MRI cannot be obtained promptly, do NOT delay steroid treatment [5]
- ABR (auditory brainstem response) is an alternative if MRI is contraindicated, though less sensitive for small lesions [2]
13. Special Tests
- Audiometry (pure tone + speech): Confirmatory test — should be obtained within 14 days of symptom onset (ideally ASAP). Diagnostic criterion: ≥30 dB loss in ≥3 consecutive frequencies [1-2]
- Bedside hearing assessment: Ask patient to hum — sound lateralizes away from the SNHL ear; compare phone hearing ear-to-ear [5]
- Tympanometry: Normal (Type A) in SNHL; helps exclude middle ear pathology
- OAE (otoacoustic emissions): Can help differentiate cochlear vs. retrocochlear pathology
- ABR: If MRI unavailable; also useful for retrocochlear screening [2]
14. ECG
- Not routinely indicated for isolated unilateral SSNHL
- Consider ECG if vascular etiology is suspected (atrial fibrillation as embolic source) or if bilateral SSNHL raises concern for vertebrobasilar ischemia [8]
- Baseline ECG reasonable before initiating high-dose steroids in patients with cardiac risk factors
15. Assessment
SSNHL is a clinical emergency with a narrow treatment window. One-third to two-thirds of patients achieve spontaneous recovery, most within the first 2 weeks. [16] However, delayed treatment significantly worsens outcomes — treatment within 3 days yields the best recovery odds (OR 0.42 vs. later treatment), and efficacy diminishes substantially beyond 14 days. [4][17]
Prognostic factors for poorer recovery:
- Profound initial hearing loss [17]
- Bilateral involvement [17]
- Delayed treatment initiation (>14 days) [4]
- Concomitant vestibular symptoms [7]
- Down-sloping audiometric configuration
A specific cause is identified in only ~10% of cases; the remainder are classified as idiopathic. [3]
16. Treatment Plan
Initial stabilization and primary therapy:
- Oral prednisone 60 mg/day (or 1 mg/kg/day, max 60 mg) for 10–14 days with taper — should be initiated as soon as SSNHL is suspected, even before audiometry or MRI [3][5]
- Intratympanic steroids (dexamethasone 10–24 mg/mL) as primary therapy if systemic steroids are contraindicated (uncontrolled diabetes, active infection, psychiatric history) [2][18]
- Combined oral + intratympanic steroids may increase the proportion of patients with hearing improvement, though evidence is low certainty [19]
Salvage therapy (incomplete recovery at 2–6 weeks):
- Intratympanic steroid injections — recommended by AAO-HNS for patients with incomplete recovery. Efficacy diminishes if initiated beyond 18 days from onset [2][17]
- Hyperbaric oxygen therapy — may be offered combined with steroids within 2 weeks (primary) or within 1 month (salvage) per AAO-HNS [20]
Do NOT prescribe: Antivirals, thrombolytics, vasodilators, or vasoactive substances [2]
Audiologic rehabilitation: For patients with residual hearing loss — hearing aids, CROS devices, or cochlear implant evaluation for profound unilateral loss [2]
17. Disposition
- Most patients can be managed as outpatients with urgent ENT referral (ideally within 1–3 days) [13]
- Admission criteria:
- Bilateral sudden hearing loss with concern for stroke or systemic disease [8]
- Focal neurologic deficits suggesting posterior fossa stroke
- Need for IV steroids or inability to tolerate oral steroids
- Severe comorbidities requiring inpatient steroid monitoring
- ENT/Otolaryngology consultation: All patients with confirmed or suspected SSNHL — urgent, not elective [13][21]
- Neurology consultation: If focal neurologic findings, bilateral hearing loss, or imaging suggests stroke/demyelination [8]
18. Follow Up / Return Precautions
- Follow-up audiometry at conclusion of treatment AND within 6 months of treatment completion [2]
- MRI with gadolinium if not yet obtained — should be completed to exclude retrocochlear pathology [2]
- Return immediately for:
- Hearing loss in the contralateral ("good") ear
- New neurologic symptoms (facial weakness, vision changes, severe headache, ataxia)
- Worsening vertigo or new-onset vertigo
- Ear pain, drainage, or fever
- Patient counseling:
- Protect the better-hearing ear — avoid excessive noise exposure and barotrauma (no scuba diving) [5]
- One-third to two-thirds of patients recover spontaneously; steroid treatment may improve odds but evidence is limited [3][16]
- Residual tinnitus is common and may benefit from audiologic rehabilitation [2]
- Expected course: Most recovery occurs within the first 2 weeks; hearing that has not recovered by 6 months is unlikely to improve further
References
1. Hearing Loss in Adults. — Cunningham LL, Tucci DL. The New England Journal of Medicine. 2017.
2. Hearing Loss in Adults. — Cunningham LL, Tucci DL. The New England Journal of Medicine. 2017.
3. Hearing Loss in Adults. — Cunningham LL, Tucci DL. The New England Journal of Medicine. 2017.
4. Clinical Practice Guideline: Sudden Hearing Loss (Update). — Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2019.
5. Clinical Practice Guideline: Sudden Hearing Loss (Update). — Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2019.
6. Sudden Sensorineural Hearing Loss. — Schreiber BE, Agrup C, Haskard DO, Luxon LM. Lancet. 2010.
7. Sudden Sensorineural Hearing Loss. — Schreiber BE, Agrup C, Haskard DO, Luxon LM. Lancet. 2010.
8. Is Sudden Sensorineural Hearing Loss an Otologic Emergency? Evidence-Based Cutoff for Optimal Treatment Initiation for Sudden Unilateral Sensorineural Hearing Loss: A Case Series and Meta-Analyses. — Klein L, Handzel O, Shilo S, et al. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society European Academy of Otology and Neurotology. 2023.
9. Is Sudden Sensorineural Hearing Loss an Otologic Emergency? Evidence-Based Cutoff for Optimal Treatment Initiation for Sudden Unilateral Sensorineural Hearing Loss: A Case Series and Meta-Analyses. — Klein L, Handzel O, Shilo S, et al. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society European Academy of Otology and Neurotology. 2023.
10. Idiopathic Sudden Sensorineural Hearing Loss. — Rauch SD. The New England Journal of Medicine. 2008.
11. Idiopathic Sudden Sensorineural Hearing Loss. — Rauch SD. The New England Journal of Medicine. 2008.
12. Sudden Sensorineural Hearing Loss in Patients Aged From 15 to 40 Years. — Aldè M, Ambrosetti U, Piatti G, et al. Journal of Clinical Medicine. 2024.
13. Sudden Sensorineural Hearing Loss in Patients Aged From 15 to 40 Years. — Aldè M, Ambrosetti U, Piatti G, et al. Journal of Clinical Medicine. 2024.
14. Audiological Outcomes of Salvage Intratympanic Corticosteroid Therapy in Idiopathic Sudden Sensorineural Hearing Loss. — Götting C, Lädrach C, Hool SL, et al. Audiology & Neuro-Otology. 2026.
15. Audiological Outcomes of Salvage Intratympanic Corticosteroid Therapy in Idiopathic Sudden Sensorineural Hearing Loss. — Götting C, Lädrach C, Hool SL, et al. Audiology & Neuro-Otology. 2026.
16. Teaching NeuroImage: Sudden Bilateral Sensorineural Hearing Loss Due to Vertebrobasilar Ischemia. — Buciuc M, Ali H, Gonzalez P, Nankee CL, Holmstedt CA. Neurology. 2023.
17. Teaching NeuroImage: Sudden Bilateral Sensorineural Hearing Loss Due to Vertebrobasilar Ischemia. — Buciuc M, Ali H, Gonzalez P, Nankee CL, Holmstedt CA. Neurology. 2023.
18. High-Dose Glucocorticoids for the Treatment of Sudden Hearing Loss. — Plontke SK, Girndt M, Meisner C, et al. NEJM Evidence. 2024.
19. High-Dose Glucocorticoids for the Treatment of Sudden Hearing Loss. — Plontke SK, Girndt M, Meisner C, et al. NEJM Evidence. 2024.
20. Clinical Practice Guideline: Age-Related Hearing Loss. — Tsai Do BS, Bush ML, Weinreich HM, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2024.
21. Clinical Practice Guideline: Age-Related Hearing Loss. — Tsai Do BS, Bush ML, Weinreich HM, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2024.
22. Risk Factors and Occurrence of Small Vessel Disease in Acute Sensorineural Hearing Loss in the Elderly: Protocol for a Multicentre Cross-Sectional Study. — Oussoren FK, van Leeuwen RB, Schermer TR, et al. BMJ Open. 2025.
23. Risk Factors and Occurrence of Small Vessel Disease in Acute Sensorineural Hearing Loss in the Elderly: Protocol for a Multicentre Cross-Sectional Study. — Oussoren FK, van Leeuwen RB, Schermer TR, et al. BMJ Open. 2025.
24. Update on Findings About Sudden Sensorineural Hearing Loss and Insight Into Its Pathogenesis. — Yamada S, Kita J, Shinmura D, et al. Journal of Clinical Medicine. 2022.
25. Update on Findings About Sudden Sensorineural Hearing Loss and Insight Into Its Pathogenesis. — Yamada S, Kita J, Shinmura D, et al. Journal of Clinical Medicine. 2022.
26. Age-Related Hearing Loss. — Lin FR. The New England Journal of Medicine. 2024.
27. Age-Related Hearing Loss. — Lin FR. The New England Journal of Medicine. 2024.
28. Clinical Reasoning: A 72-Year-Old Woman With Rapidly Progressive Bilateral Hearing Loss. — Alsalem A, Marzoughi S, Chen T. Neurology. 2022.
29. Clinical Reasoning: A 72-Year-Old Woman With Rapidly Progressive Bilateral Hearing Loss. — Alsalem A, Marzoughi S, Chen T. Neurology. 2022.
30. Contemporary Review of the Causes and Differential Diagnosis of Sudden Sensorineural Hearing Loss. — Young YH. International Journal of Audiology. 2020.
31. Contemporary Review of the Causes and Differential Diagnosis of Sudden Sensorineural Hearing Loss. — Young YH. International Journal of Audiology. 2020.
32. Management of Sudden Sensorineural Hearing Loss. — Metrailer AM, Babu SC. Current Opinion in Otolaryngology & Head and Neck Surgery. 2016.
33. Management of Sudden Sensorineural Hearing Loss. — Metrailer AM, Babu SC. Current Opinion in Otolaryngology & Head and Neck Surgery. 2016.
34. Intratympanic Steroid Administration and Predictors of Recovery in Sudden Sensorineural Hearing Loss. — Kennedy DJ, Williams E, Wolf L, et al. PloS One. 2025.
35. Intratympanic Steroid Administration and Predictors of Recovery in Sudden Sensorineural Hearing Loss. — Kennedy DJ, Williams E, Wolf L, et al. PloS One. 2025.
36. Intratympanic vs Systemic Corticosteroids in First-line Treatment of Idiopathic Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. — Mirian C, Ovesen T. JAMA Otolaryngology-- Head & Neck Surgery. 2020.
37. Intratympanic vs Systemic Corticosteroids in First-line Treatment of Idiopathic Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. — Mirian C, Ovesen T. JAMA Otolaryngology-- Head & Neck Surgery. 2020.
38. Intratympanic Corticosteroids for Sudden Sensorineural Hearing Loss. — Plontke SK, Meisner C, Agrawal S, et al. The Cochrane Database of Systematic Reviews. 2022.
39. Intratympanic Corticosteroids for Sudden Sensorineural Hearing Loss. — Plontke SK, Meisner C, Agrawal S, et al. The Cochrane Database of Systematic Reviews. 2022.
40. Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary. — Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2019.
41. Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary. — Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2019.
42. Hearing Loss in Adults: Differential Diagnosis and Treatment. — Michels TC, Duffy MT, Rogers DJ. American Family Physician. 2019.
43. Hearing Loss in Adults: Differential Diagnosis and Treatment. — Michels TC, Duffy MT, Rogers DJ. American Family Physician. 2019.